Andrew Hill Investment Advisors has released its third-quarter 2026 investor letter, reviewing a market pulled in competing directions. Rising oil prices, higher interest rates, and persistent inflation weighed on stocks and bonds, while resilient corporate earnings and continued investment in artificial intelligence supported the broader equity market.
The letter does not report an aggregate third-quarter return for client portfolios. For context, the S&P 500 gained 3.54% through September 22, while the Bloomberg U.S. Aggregate Bond Index declined 2.8%. Oil prices climbed sharply, and the Federal Reserve raised its benchmark rate to 3.75%–4.00%, which the letter describes as its first increase in more than three years.
Exposure to software, AI hardware, and selected strategic investments supported client account performance, although losses elsewhere and rising bond yields offset some gains. The letter highlights a pronounced divide between investment themes: an equal-weight basket of AI stocks returned an average of 13.0% during the quarter, compared with an 8.3% decline for a basket of traditional-economy stocks.
Looking ahead, the firm expects the AI investment cycle to continue but remains cautious about the broader stock market. Its concerns include higher rates, inflation, geopolitical tensions, constrained consumer spending, election uncertainty, and a potential slowdown in AI capital spending as additional computing capacity becomes available. Against that backdrop, Andrew Hill favors companies with solid earnings, higher cash balances, and a gradual increase in fixed-income exposure, noting that high-grade corporate bonds offer yields above 6%.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotechnology company that develops and markets treatments for serious diseases, including cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. Its established cystic fibrosis business supports its expansion into additional specialty medicine markets. On October 29, 2026, its shares closed at $540.00, an increase of 1.95% from the previous session, giving the company a market capitalization of approximately $136.87 billion.
Here’s what Andrew Hill Investment Advisors has to say about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX):
“Vertex remains the leader in cystic fibrosis treatments, a franchise that generates substantial cash flow and provides the company with the resources to expand into new therapeutic areas. As the company looks beyond its core business, management has been actively deploying capital through acquisitions and internal research efforts to build a broader portfolio of therapies. These investments span areas such as kidney disease, pain management, gene editing, and other high-value specialty indications. We believe the market continues to view Vertex primarily through the lens of its cystic fibrosis franchise, while underappreciating the company’s growing collection of future growth drivers.
On October 23, 2026, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced that results from its Phase 3 RAINIER trial of povetacicept, an investigational treatment for IgA nephropathy, were published in the New England Journal of Medicine. The interim analysis showed a 49.8% reduction in proteinuria versus placebo at 36 weeks, meeting the trial’s primary endpoint. The company said the treatment remained on track for an FDA target decision date of November 30, 2026, for potential accelerated approval, representing a possible expansion beyond its established cystic fibrosis franchise.
YOU MUST READ THIS: 10 Best Stocks to Buy for the Next 20 Years
Disclosure: No material interests to disclose. This article was originally published on Global Market Bulletin.
